RxDoctor Payments Data

Jennifer Maag, MD

Family Medicine · Ottawa, OHNPI 1689841900

Payments from drug & device makers

$325in general payments, 2019–2025

Across 22 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$74
  • AstraZeneca$51
  • Edwards Lifesciences$45
  • Boehringer Ingelheim$39
  • Bayer$20
  • Otsuka America Pharmaceutical, Inc.$19
  • plus $78 from 6 others

What the payments were for

  • Food & beverage$30594%
  • Education$206%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$325 in reported general payments places this provider in the 45th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$66,728
Medicare patients
283
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate46$137,915
EnbrelEtanercept13$100,661
JardianceEmpagliflozin157$98,575
EliquisApixaban68$67,334
StribildElviteg/Cob/Emtri/Tenofo Disop12$52,973
NuedextaDextromethorphan Hbr/Quinidine65$50,749
AristadaAripiprazole Lauroxil18$50,346
FarxigaDapagliflozin Propanediol86$48,802
TradjentaLinagliptin139$40,221
TrulicityDulaglutide23$38,373
JanuviaSitagliptin Phosphate62$31,581
XareltoRivaroxaban49$30,900
VraylarCariprazine Hcl37$26,686
OzempicSemaglutide19$26,483
Risperdal ConstaRisperidone Microspheres19$24,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta$17$193,747114 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$39$151,917310 claims
AstraZenecaFarxiga, Daliresp, Symbicort$51$61,131131 claims
Lilly USA, LLCTrulicity, Olanzapine$11$47,027183 claims
AbbVieVraylar, Linzess, Fetzima$12$45,63782 claims
MerckJanuvia$11$31,58162 claims
Novo NordiskOzempic$74$26,48319 claims
Otsuka America Pharmaceutical, Inc.Rexulti$19$19,53634 claims
NovartisEntresto$15$10,93132 claims
GSKIncruse Ellipta$12$6,19817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Ottawa

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →